Australian bio company currently in negotiations both in Australia, Europe and America to license and distribute their autostart burettes and autoflush products.
- FDA approved - Saves 20 minutes nurse time per patient - Product superior to standard burette - Product cheaper and cost efficient (savings up to $60 per device in labor and parts, only costs $5-$6) - $3Bn annual market - Currently used by NSW Ambulance and Concord Hospital - World class manufacturer in China
Reasons for anticipated move
- Negotiations with QLD Health (180 hospitals) - Conducting trial at RPA in Sydney (tv exposure ?) - Unknown other trials in Brisbane and Sydney - In discussions with Major(s) in US
News is expected on the above 4. All have the potential to push the price through previous resistance at 3.4c. Any MOU or HOA with a major (i.e Baxter, J&J) then real potential to push to 5 - 6c.
IMO current levels provide good risk v reward entry price considering above mentioned.
